

MAY 11 2004

9. 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

This summary of safety and effectiveness information is being submitted in accordance with the requirements of The Safety Medical Devices Act of 1990 (SMDA 1990) and 21 CFR Part 807.92.

Assigned 510(k) Number: K040449

Date of Summary Preparation: February 12, 2004

Manufacturer: Pharmacia Deutschland GmbH,
Diagnostics Division
Munzinger Strasse 7
D-79111 Freiburg, Germany

Company Contact Person: Michael Linss
Manager, Regulatory Affairs
Pharmacia Deutschland GmbH
Diagnostics Division
Munzinger Strasse 7
D-79111 Freiburg, Germany
+49-761-47805-310 (Phone)
+49-761-47805-120 (Fax)

Device Name: Varelisa® B2 Glycoprotein I IgG Antibodies

Common Name: B2 Glycoprotein I autoantibody
immunological test system

Classification:

<u>Product Name</u>	<u>Product Code</u>	<u>Class</u>	<u>CFR</u>
Varelisa® B2 Glycoprotein I IgG Antibodies	MSV	II	866.5560

Substantial Equivalence to

INOVA QUANTA LITE™ B2 GPI (IgG) Antibodies

Intended Use Statement

The Varelisa β 2-Glycoprotein I IgG Antibodies EIA kit is designed for the semiquantitative and qualitative determination of β 2-glycoprotein I IgG antibodies in serum or plasma.

The presence of β 2-glycoprotein I antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of thrombotic disorders related to the primary Antiphospholipid Syndrome or occurring secondary to systemic lupus erythematosus (SLE) or other autoimmune diseases.

General Description of the Device

The Varelisa β 2-Glycoprotein I IgG Antibodies Assay is an indirect noncompetitive enzyme immunoassay for the semiquantitative and qualitative determination of β 2-glycoprotein I IgG antibodies in serum or plasma.

The test kit contains microplate strips coated with human purified β 2-glycoprotein I, calibrators, positive and negative controls, enzyme-labeled conjugate, substrate and substrate stop solution, buffered diluent and wash buffer.

Varelisa® β 2-Glycoprotein IgG Antibodies Test Principle

Varelisa β 2-Glycoprotein I IgG Antibodies is an indirect noncompetitive enzyme immunoassay for the semiquantitative and qualitative determination of β 2-glycoprotein I IgG antibodies in human serum or plasma. The wells of a microplate are coated with human purified β 2-glycoprotein I antigen. Antibodies specific for β 2-glycoprotein I present in the patient sample bind to the antigen.

In a second step the enzyme labeled second antibody (conjugate) binds to the antigen-antibody complex which leads to the formation of an enzyme labeled conjugate-antibody-antigen complex. The enzyme labeled antigen-antibody complex converts the added substrate to form a colored solution.

The rate of color formation from the chromogen is a function of the amount of conjugate complexed with the bound antibody and thus is proportional to the initial concentration of the respective antibodies in the patient sample.

Device Comparison

Both assays (the predicate and the new device) are indirect noncompetitive enzyme immunoassays for the semiquantitative and qualitative determination of IgG antibodies against β 2-glycoprotein I in serum. Both assays recommend the same sample dilutions and use comparable enzyme-linked conjugates and antigens.

Based on currently available data from the literature the measuring of the antibodies against β 2-glycoprotein I not only provides aid in the diagnosis of thrombotic disorders secondary to systemic lupus erythematosus or other autoimmune diseases, but also aids in the diagnosis of the primary

Varelista® β 2 Glycoprotein I IgG Antibodies – New Device
510(k) Submission
Section 9. Summary of Safety and Effectiveness

antiphospholipid syndrome. Thus the intended use of Varelista β 2-glycoprotein I Antibodies Screen was adapted to the current state of scientific knowledge. The corresponding literature is cited in the directions for use.

A difference between both assays is that the INOVA QUANTA Lite™ β 2 GPI IgG is only recommended for use in serum specimen while the PHARMACIA Varelista β 2-glycoprotein I IgG Antibodies is outlined for use with serum and plasma. Corresponding performance data underline the effectiveness of the assay with plasma as sample. Minor differences between both assays are restricted to contents of buffers and stop solution. The INOVA QUANTA Lite™ β 2 GPI IgG assay is evaluated by using the decision point method. PHARMACIA Varelista β 2-glycoprotein I IgG Antibodies assay uses an ODcut-off for evaluation. Corresponding performance data show the comparability of the results.

Laboratory equivalence

The comparability of QUANTA Lite™ β 2 GPI IgG and Varelista β 2-Glycoprotein I IgG Antibodies is supported by a data set including

- results obtained within a comparison study analyzing positive, equivocal and negative sera.
- results obtained for externally defined Calibrators.
- results obtained for samples from apparently healthy subjects (normal population).

The data show that the assay performs as expected from the medical literature. Furthermore the data show that the device is suitable for serum and plasma samples.

In summary, all available data support that the new device, PHARMACIA Varelista β 2-Glycoprotein I IgG Antibodies Assay is substantially equivalent to the predicate device, INOVA QUANTA Lite™ β 2 GPI IgG Assay, and that the new device performs according to state-of-the-art expectations.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

MAY 11 2004

Michael Linss, Ph.D.
Manager, Compliance & Quality
Pharmacia Deutschland GMBH
Diagnostics Division
Munzinger Strasse 7
Freiburg,
Germany D-79111

Re: k040449
Trade/Device Name: Varelisa® B2 Glycoprotein I IgG Antibodies
Regulation Number: 21 CFR 866.5660
Regulation Name: Multiple autoantibodies immunological test system
Regulatory Class: Class II
Product Code: MSV
Dated: April 27, 2004
Received: April 30, 2004

Dear Dr. Linss:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink, reading "Joseph L. Hackett". The signature is written in a cursive style with a large, stylized "J" and "H".

Joseph L. Hackett, Ph.D.
Acting Director
Division of Immunology and Hematology Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Varelisa® β 2 Glycoprotein I IgG Antibodies- New Device
510(k) Submission
Section 1. Indications for Use Statement

510(k) Number: K040449

Device Name: **Varelisa® β 2 Glycoprotein I IgG Antibodies**

Intended Use Statement

The Varelisa β 2-Glycoprotein I IgG Antibodies EIA kit is designed for the semiquantitative and qualitative determination of β 2-glycoprotein I IgG antibodies in serum or plasma.

The presence of β 2-glycoprotein I antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of thrombotic disorders related to the primary Antiphospholipid Syndrome or occurring secondary to systemic lupus erythematosus (SLE) or other autoimmune diseases.

Maria Chan

Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K040449

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER
PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒

OR

Over-The-Counter Use ☐

(Per 21 CFR 801.109)